Global Cardiovascular Genetic Testing Market Industry Overview and Forecasts to 2031 – Market Analysis and Market Share

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Cardiovascular Genetic Testing Market Industry Overview and Forecasts to 2031 – Market Analysis and Market Share

  • Healthcare
  • Upcoming Report
  • Aug 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Cardiovascular Genetic Testing Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2024 –2031
Diagram Market Size (Base Year)
USD 9.07 Billion
Diagram Market Size (Forecast Year)
USD 19.07 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

The Global Cardiovascular Genetic Testing Market was valued at USD 9.07 billion in 2023. The market size is projected to grow at a CAGR of 11.20% to reach USD 19.07 billion by 2031.

Cardiovascular Genetic Testing Market

Global Cardiovascular Genetic Testing Market - Industry Overview

Cardiovascular Genetic Testing helps to determine the genetic risk of a person concerning coronary artery disease, hypertension, cardiomyopathies, and several other disorders relating to the cardiovascular system. Since cardiovascular disorders are permeating the global population swiftly, early identification allows health professionals to develop preventive measures more effectively. Here genetic testing becomes important in assessing an individual's genetic risk for certain disorders. If we go by the figures, cardiovascular disease claims the lives of around 17.9 million people annually and is the leading cause of death globally. Heart and vascular disorders, together referred to as cardiovascular diseases, comprise coronary heart disease, cerebrovascular disease, and rheumatic heart disease. Surveys conducted by the World Health Organization (WHO) predict that by 2030, the number of deaths worldwide from cardiovascular disease would surpass 23 million.

Data Bridge Market research market report provides details of recent developments, trade regulations, market share, market trends on the basis of its segmentations and regional analysis, impact of market players, analysis of opportunities in terms of emerging revenue pockets, market regulations, strategic market growth analysis, market size, category wise market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research’s team of expert analysts. Our team will help you make informed market decisions to achieve business growth.

Global Cardiovascular Genetic Testing Market Size and Market Analysis

Global Cardiovascular Genetic Testing Market Report Metrics Details

Forecast Period

2024-2031

Base Year

2023

Historic Year

2022 (Customizable 2016-2021)

Measuring Unit

USD Billion

Data Pointer

Market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Cardiovascular Genetic Testing market is also benefiting from reduced testing costs and expanded accessibility, alongside heightened awareness among patients and healthcare professionals about the benefits of genetic insights as a result. Data bridge Market Research took a dive into comprehensively analyzing the market and unveiled that the Global Cardiovascular Genetic Testing market is increasing at a CAGR of 11.20%. The size of the market is valued at USD 9.07 billion in 2023 and is expected to grow up to USD 19.07 billion by 2031.

Global Cardiovascular Genetic Testing Market Dynamics

Global Cardiovascular Genetic Testing Market Growth Drivers

Rising Incidence of Cardiovascular Diseases

Cardiovascular Genetic testing is becoming more and more necessary in order to identify those who are at higher risk developing such disorders. Timely diagnosis propels having preventive measures in the early stages, thereby curbing the rising prevalence of cardiovascular illnesses such as heart failure, hypertension, and coronary artery disease. According to (WHO) World Health Organization coronary artery disease (CAD) is increasing globally, with an estimated 18.6 million deaths attributed to cardiovascular diseases each year.

Increasing Utilization of Minimally Invasive Techniques

One of the emerging segments within the cardiovascular devices industry is created by the increasing demand for minimally invasive procedures, which involve catheter-based interventions and robot-assisted surgeries, among others. Advancements offer a number of advantages with regard to fast recovery, lesser complication risks, and shorter hospitalization, thereby increasing the scope of cardiovascular care applications.

 Wellness and Preventive Health Initiatives

People are becoming more interested in knowing their hereditary risk factors in order to take proactive steps to maintain cardiovascular health as preventative healthcare takes relevance. Initiatives centered around wellness and preventative health raise awareness of the value of proactive healthcare. People are starting to realize how important it is to keep an eye on their health and take preventative action to lower their chance of illness. Reactive healthcare is becoming less popular in favor of preventive healthcare. People are searching for strategies to recognize health hazards at an early stage and take preventative measures to avoid diseases, such as cardiovascular disorders.

Global Cardiovascular Genetic Testing Market Growth Opportunities

Improved Healthcare Access and Affordability

Cardiovascular genetic testing market has a lot of potential because of the initiatives taken by governments and the business sector in emerging nations to lower the cost of and increase access to sophisticated healthcare. These initiatives are reaching a larger population by making the integration of genetic testing into standard medical care a priority. The need for genetic testing as a component of regular health evaluations is driven by this push for affordability and inclusivity, creating new markets for companies who deliver these technologies. Significant development opportunities exist for businesses in the cardiovascular genetic testing industry as a result of the greater accessibility and integration of genetic testing, which can improve early illness identification and individualized treatment as healthcare systems in these areas change.

Global Cardiovascular Genetic Testing Market Growth Challenges

Data Management and Interpretation

Large volumes of genetic data and complicated patterns within the intricacy of this data might be overwhelming for healthcare professionals who do not have the tools or expertise to fully understand it. This can make it more difficult for clinicians to make clinical decisions since they have to incorporate the genetic test results into patient care plans in addition to comprehending the intricacies of the results. This could make it difficult to use genetic testing effectively and efficiently in clinical practice.

Patient and Provider Acceptance

Inadequate education and awareness are a key impediment to the growth and effectiveness of the global market for cardiovascular genetic testing. Lower adoption rates may arise from healthcare providers' reluctance to propose genetic testing if they are not fully aware of how it might improve diagnosis, treatment, and prevention. Similar to this, even when recommended, patients who lack knowledge about the advantages and restrictions of genetic testing may not explore or fully utilize these choices.

Global Cardiovascular Genetic Testing Market Size Growth Restraints

Ethical and Privacy Concerns

Global Cardiovascular Genetic Testing brings up ethical concerns related to the privacy and security of personal genetic information. The handling of sensitive data, including an individual's genetic code, raises worries about how this information might be used or shared. As incidents of data breaches and misuse of personal information become more frequent, these concerns grow. Patients may be reluctant to undergo genetic testing if they are concerned about the potential exposure or misuse of their genetic data, which could discourage participation in these tests. This report on the global cardiovascular genetic testing market offers insights into recent developments, trade regulations, and import-export dynamics. It includes an analysis of production, value chain optimization, market share, and the impact of both domestic and regional players.

Expensive cost of treatment

Cardiovascular Genetic testing are expensive to conduct and require a lot of input. Testing is hence costly. Depending on the condition and test type, genetic testing costs can vary and could be very high.  Developing nations also have to deal with the issue of genetic testing being quite expensive. For example, in India, the cost of a genetic test might range higher than the standard affordable value making it an unaffordable alternative.

Global Cardiovascular Genetic Testing Market Scope and Trends

Global Cardiovascular Genetic Testing Market Segmentations Overview

Segments Type

Sub-Segments

Disease

Inherited Cardiomyopathies, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Arrhythmia, Aortopathies, Others

Technology

Cytogenetic Testing, Biochemical Testing, Molecular Testing

Testing Type

Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Others

Application

Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Others

 

 

 

 

 

 

 

 

 

 

Key Insight

  • Biochemical tests measure biomarkers such as troponins, which signal cardiac stress or damage, and natriuretic peptides, which indicate heart failure. These biomarkers offer additional context about the severity of cardiovascular conditions identified through genetic testing. For instance, if genetic testing detects a mutation associated with Hypertrophic Cardiomyopathy (HCM), biochemical tests can evaluate how this mutation is affecting the patient's heart function, providing a more comprehensive understanding of the disease.
  • Cardiovascular Genetic testing can detect specific mutations or variations in genes linked to cardiovascular diseases, including hypertrophic cardiomyopathy, familial hypercholesterolemia, and arrhythmias. Identifying these genetic risks enables early diagnosis and intervention, allowing for timely management of these conditions.
  • Incorporating cardiovascular genetic testing into routine healthcare, populations can undergo more comprehensive screening, facilitating earlier detection and treatment of cardiovascular diseases. This proactive approach enhances the management of these conditions and contributes to improved public health outcomes.
  • The cardiovascular genetic testing market facilitates the development and growth of genomic databases that compile genetic variants linked to cardiovascular diseases. These databases are essential for discovering new biomarkers and enhancing the precision of molecular diagnostic tests.

Global Cardiovascular Genetic Testing Market Regional Analysis – Market Trends

Global Cardiovascular Genetic Testing Market Regional Overview

Regions

Countries

Europe

Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe

APAC

China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific

North America

U.S., Canada, and Mexico

MEA

Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East, and Africa

South America

Brazil, Argentina, and Rest of South America

 

 

 

 

 

 

 

 

 

 

 

Key Insights

  • Europe excels in cardiovascular genetic testing market research, supported by a multitude of academic and research institutions dedicated to exploring genetic factors in cardiovascular diseases. This vibrant research ecosystem drives innovation, leading to the development of advanced genetic tests and cutting-edge technologies.
  •  Despite the growth potential, the uniform adoption of cardiovascular genetic testing technologies is challenged by inconsistent reimbursement levels across countries, varying national regulations, and the necessity for healthcare professionals to receive adequate training in genetic testing.
  • North America, United States and Canada, boasts a highly advanced healthcare system with sophisticated infrastructure that facilitates the integration of cardiovascular genetic testing into clinical practice.
  • North America hosts premier research institutions and biotechnology firms that spearhead innovation in genetic testing. This strong focus on research and development results in the creation of state-of-the-art tests and technologies.
  • APAC countries are making substantial investments in healthcare infrastructure and biotechnology, which enhances the development and implementation of cardiovascular genetic testing technologies within clinical settings.

Global Cardiovascular Genetic Testing Market Leading Players

  • Bio-Rad Laboratories Inc. (U.S.)
  • Danaher (U.S.)
  • Daan Gene Co., Ltd. (Canada)
  • F. Hoffmann-La Roche, Ltd. (Switzerland)
  • Genentech, Inc. (U.S.)
  • Genomictree, Inc. (South Korea)
  • HTG Molecular Diagnostics, Inc. (U.S.)
  • Illumina, Inc. (U.S.)
  • Integragen (France)
  • Laboratory Corporation of America Holdings (U.S.)
  • Luminex Corporation (U.S.)
  • Molecular MD Corp. (U.S.)
  • Myriad Genetics, Inc. (U.S.)
  • Natera, Inc. (U.S.)
  • Oxford Biodynamics Plc (U.K)
  • PacBio (U.S.)
  • PerkinElmer Inc. (U.S.)
  • Qiagen (Germany)
  • Thermo Fisher Scientific, Inc. (U.S.)

Recent Developments in Global Cardiovascular Genetic Testing Market

  • The use of polygenic risk scores (PRS) is increasingly common. PRS evaluate the cumulative impact of various genetic variants on an individual’s risk for cardiovascular conditions, thereby enhancing risk assessment and enabling more personalized treatment strategies.
  • The In Vitro Diagnostic Regulation (IVDR), effective from May 2022, establishes stricter criteria for the approval and oversight of in vitro diagnostic tests, including genetic tests. These enhanced standards improve the accuracy, reliability, and safety of genetic testing products, influencing their validation processes and market entry.
  • The updated GDPR and similar data protection laws require more stringent safeguards for genetic data, ensuring that patient information used in cardiovascular genetic testing is collected, stored, and processed with enhanced security. These regulations have strengthened privacy protections for individuals undergoing cardiovascular genetic testing.

DBMR’s market report on cardiovascular genetic testing market takes you through valuable insights that can contribute to making several important business decisions. Based on our reports and research expertise you can create realistic growth strategies for your business.    


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Global Cardiovascular Genetic Testing Market is growing at a CAGR 11.20% and is expected to reach 9.07 in 2024.
The Global Cardiovascular Genetic Testing Market is growing CAGR of 11.20%. The market is valued at 8.15 billion and is expected to reach USD 19.07 billion by 2031.
Key drivers include innovative forming techniques, Rising Incidence of Cardiovascular Diseases, Increasing Utilization of Minimally Invasive Techniques, Health and Wellness Prevention Programs.
APAC, the demand for genetic testing is being driven by factors such as lifestyle changes, urbanization, and an aging population, which contribute to the need for early diagnosis and personalized treatment.
Our TRIPOD analysis involves comprehensive primary as well as secondary research to gather the data that is analyzed using credible data analysis methodologies involving Data Forecast Modelling, Porter’s Five Force Model, Demand Supply Chain Analysis, and Value Change Analysis.